Cargando…
Long‐term (>5‐year) survivors among unresectable or metastatic cancer patients treated with zoledronate‐activated killer cells: Seven case reports
We are conducting an adoptive immunotherapy (AIT) trial using zoledronate‐activated killer cells for patients in Japan with incurable cancer. We have encountered seven long‐term survivors. Since such long survival may be very rare in cancer treatment, we present the details and a discussion of a pos...
Autor principal: | Yamaguchi, Yoshiyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664521/ https://www.ncbi.nlm.nih.gov/pubmed/36397848 http://dx.doi.org/10.1002/ccr3.6540 |
Ejemplares similares
-
Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational study
por: Yamaguchi, Yoshiyuki, et al.
Publicado: (2020) -
Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational study
por: Yamaguchi, Yoshiyuki, et al.
Publicado: (2022) -
Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid
por: Yanae, Masashi, et al.
Publicado: (2017) -
Long-Term Survivors with Metastatic Uveal Melanoma
por: Buzzacco, Dominic M, et al.
Publicado: (2012) -
Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report
por: Tokumaru, Yoshihisa, et al.
Publicado: (2019)